ARHGAP22

Across TCGA pan-cancer cohorts, ARHGAP22 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARHGAP22 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGAP22 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGAP22 expression acts as an unfavorable survival marker.

CCRCC, HNSC, and PDAC are the cancer types where ARHGAP22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.840	1.000	.004	8	view →
HNSC	OS	Median	All	0.834	0.964	.036	4	view →
PDAC	OS	Tertile	II,III,IV	0.463	0.672	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARHGAP22–CCRCC (OS)

Open the CCRCC breakdown →